文献速递糖尿病肥胖与代谢综合征

索格列净对主要不良心血管事件的影响:SCORED随机试验的预设次要分析

Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial.
PubMed 文献 · Lancet Diabetes Endocrinol · 2025-02-14

SCORED试验的预设次要分析纳入10584例2型糖尿病合并慢性肾脏病及额外心血管风险患者,随机接受索格列净或安慰剂。索格列净组总主要不良心血管事件发生率显著低于安慰剂组(4.8 vs 6.3事件/100人年;HR 0.77,95%CI 0.65-0.91;p=0.0020),心肌梗死和卒中发生率亦显著降低。

要点

  • 索格列净降低总主要不良心血管事件(HR 0.77,95%CI 0.65-0.91;p=0.0020)。
  • 索格列净降低心肌梗死(HR 0.68,95%CI 0.52-0.89;p=0.0041)。
  • 索格列净降低卒中(HR 0.66,95%CI 0.48-0.91;p=0.012)。

核心结论

  • 在2型糖尿病、慢性肾脏病及额外心血管风险患者中,索格列净降低主要不良心血管事件,并独立降低心肌梗死和卒中。
  • 其他SGLT抑制剂尚未观察到对心肌梗死和卒中的双重缺血获益,值得研究SGLT1和SGLT2联合抑制作为可能机制。

研究设计与样本

  • SCORED试验的预设次要分析,该试验为双盲、安慰剂对照、随机临床试验。
  • 纳入年龄≥18岁、2型糖尿病、慢性肾脏病(eGFR 25-60 mL/min/1.73 m2)及额外心血管风险因素的患者。
  • 44个国家750个中心,2017年12月8日至2020年1月20日入组10584例,按1:1随机分配至索格列净(n=5292)或安慰剂(n=5292)。
  • 索格列净起始200 mg每日一次,耐受者6个月内增至400 mg每日一次;安慰剂频率匹配。
  • 主要分析为意向性治疗,采用竞争风险比例风险模型;总MACE在预设亚组中分析。

主要发现

  • 中位年龄69岁(IQR 63-74);女性4754例(44.9%),男性5830例(55.1%)。
  • 5144例(48.6%)有心血管疾病史,其中心肌梗死史2108例(占总人群19.9%),卒中史946例(8.9%),冠状动脉血运重建史2375例(22.4%)。
  • 索格列净组总MACE发生率4.8事件/100人年 vs 安慰剂组6.3事件/100人年(HR 0.77,95%CI 0.65-0.91;p=0.0020)。
  • 索格列净组心肌梗死发生率1.8事件/100人年 vs 安慰剂组2.7事件/100人年(HR 0.68,95%CI 0.52-0.89;p=0.0041)。
  • 索格列净组卒中发生率1.2事件/100人年 vs 安慰剂组1.8事件/100人年(HR 0.66,95%CI 0.48-0.91;p=0.012)。

关键数值与推荐

  • 总主要不良心血管事件定义为心血管死亡、非致死性心肌梗死和非致死性卒中的复合终点,评估首次及后续事件。
  • 心肌梗死和卒中(致死性和非致死性)为事后个体终点。
  • 交互分析提示索格列净对总MACE的效应在各分层亚组间一致,无 heterogeneity 证据。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • SCORED试验因资金丧失而提前终止。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sodium-glucose co-transporter (SGLT)-2 inhibitors have shown consistent benefit in improving heart failure-related outcomes but not ischaemic cardiovascular events such as myocardial infarction or stroke. We assessed if the dual SGLT1/2 inhibitor sotagliflozin improves ischaemic outcomes. METHODS: We did a prespecified secondary analysis of the SCORED trial, which was a double-blind, placebo-controlled, randomised clinical trial enrolling patients (aged ≥18 years) with type 2 diabetes, chronic kidney disease (estimated glomerular filtration rate [eGFR] 25-60 mL/min per 1·73 m2), and additional cardiovascular risk factors. Patients at 750 sites in 44 countries were randomly assigned (1:1) to oral sotagliflozin or placebo via an interactive response technology system (block size of four; stratified by heart failure-related criteria and geographical region), with participants, investigators, and study staff, including those who assessed outcomes, masked to group assignment. Sotagliflozin treatment was prescribed at 200 mg once a day, with the dose increased to 400 mg once a day within the first 6 months if tolerated. Matching placebo was prescribed at the same treatment frequency as the intervention regimen. A prespecified secondary outcome was total major adverse cardiovascular events (MACE), which was defined as a composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke, assessed as first and subsequent events. Other outcomes included total myocardial infarction and total stroke (fatal and non-fatal events) as individual post-hoc endpoints. Outcomes were assessed by intention to treat with competing-risk proportional hazard models in the overall population, and, for total MACE, in prespecified subgroups stratified by baseline demographic and clinical features (sex, age, geographical region, heart failure-related criteria, eGFR, urine albumin-creatinine ratio, and cardiovascular disease history). The SCORED trial was registered at ClinicalTrials.gov, NCT03315143, and was ended early due to loss of funding. FINDINGS: 10 584 patients were enrolled and randomly assigned to sotagliflozin (n=5292 [50·0%]) or placebo (n=5292 [50·0%]) between Dec 8, 2017 and Jan 20, 2020 (median age 69 years [IQR 63-74]; 4754 [44·9%] female patients and 5830 [55·1%] male patients). 5144 (48·6%) patients had a history of cardiovascular disease, of whom 2108 (19·9% of the total population) had a history of myocardial infarction, 946 (8·9%) had a history of stroke, and 2375 (22·4%) had a history of coronary revascularisation. Patients in the sotagliflozin group had a significantly lower rate of total MACE than those in the placebo group (4·8 events per 100 person-years vs 6·3 events per 100 person-years; hazard ratio [HR] 0·77 [95% CI 0·65-0·91]; p=0·0020). Interaction analyses suggested a consistent effect of sotagliflozin on total MACE among stratified subgroups without evidence of heterogeneity. Additionally, sotagliflozin significantly reduced the rate of myocardial infarction (1·8 events per 100 person-years vs 2·7 events per 100 person-years; HR 0·68 [0·52-0·89]; p=0·0041) and stroke (1·2 events per 100 person-years vs 1·8 events per 100 person-years; HR 0·66 [0·48-0·91]; p=0·012) compared with placebo. INTERPRETATION: Sotagliflozin reduced MACE, with independent reductions in myocardial infarction and stroke, among patients with type 2 diabetes, chronic kidney disease, and additional cardiovascular risk. The ischaemic benefit on both myocardial infarction and stroke has not been previously observed with other SGLT inhibitors and warrants investigation of combined SGLT1 and SGLT2 inhibition as a possible underlying mechanism. FUNDING: Lexicon Pharmaceuticals.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Aggarwal R, Bhatt DL, Szarek M, et al. Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial. Lancet Diabetes Endocrinol. 2025. PMID: 39961315. doi:10.1016/S2213-8587(24)00362-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。